• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    IPA Announces Resignation of Chief Financial Officer

    12/31/24 7:56:00 PM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IPA alert in real time by email

    ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time.

    "Kristin has been a valued member of our team over this past year," said Dr. Jennifer Bath, IPA's President and Chief Executive Officer. "She has made significant contributions to IPA's success, including the enhancement of IPA's planning and budgeting process. We wish her the very best in her future endeavors."

    IPA has initiated a CFO succession process and will provide updates as appropriate.

    About ImmunoPrecise Antibodies Ltd.

    ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the "IPA Family").

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as "expects", "estimates", "intends", "anticipates", or "believes", or variations of such words and phrases, or state that certain actions, events, or results "may", "would", "might", or "will" be taken, occur, or be achieved. Forward-looking statements include, but are not limited to, the expected results of our search for a successor to the Chief Financial Officer, the results from our financial strategy and growth objectives. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions and the impact of general economic, industry or political conditions in the United States, Canada or internationally. You should also consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties.

    Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results could differ materially from those currently anticipated due to several factors and risks, as discussed in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (which may be viewed on the Company's SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this release. Accordingly, readers should not place undue reliance on forward-looking statements contained in this release. The forward-looking statements contained in this release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241231517081/en/

    Get the next $IPA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IPA

    DatePrice TargetRatingAnalyst
    12/2/2022$9.00Buy
    H.C. Wainwright
    10/25/2021$12.00Buy
    Benchmark
    10/25/2021$12.00Buy
    The Benchmark Company
    More analyst ratings

    $IPA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on ImmunoPrecise Antibodies with a new price target

    H.C. Wainwright initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $9.00

    12/2/22 8:15:24 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benchmark initiated coverage on ImmunoPrecise Antibodies with a new price target

    Benchmark initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

    10/25/21 7:31:59 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Benchmark Company initiated coverage on ImmunoPrecise Antibodies with a new price target

    The Benchmark Company initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

    10/25/21 7:28:32 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPA
    SEC Filings

    View All

    SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

    6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

    8/6/25 9:45:58 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

    6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

    8/1/25 9:25:09 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

    6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

    7/29/25 8:30:56 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

    ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a biotherapeutics company delivering advanced solutions in biologics and drug discovery, today announced the successful sale of its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe"), to AVS Bio for a total enterprise value of $12 million USD. AVS Bio, a portfolio company of Arlington Capital Partners, is a leading global provider of critical inputs and services for the bioprocessing and biologics industries. The transaction generated $11.7 million USD in net proceeds on a cash-free, debt-free basis. This transaction marks a meaningful step in IPA's strategic refinement—streamlining its o

    8/6/25 8:00:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

    Arlington Capital Partners ("Arlington"), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced that its portfolio company AVS Bio, a leading global provider of critical inputs and services for the bioprocessing and biologics industries, acquired ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe" or the "Company"). IPA Europe is a carve-out of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), a biotherapeutics company leveraging proprietary technologies, including its LENSai™ platform, to accelerate the discovery of next-generation biologics. The acquisition expands AVS Bio's European footprint and adds advanced capabilities in antibody

    8/6/25 8:00:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

    ImmunoPrecise Antibodies Ltd. ("IPA", "Company", "we" or "us") (NASDAQ:IPA), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announces its financial results for the fiscal year ended April 30, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. Financial Highlights: Achieved strong revenue for Fiscal Year 2025 of $24.5 million Delivered highest-ever fourth quarter revenue of $7.0 million Reported record fourth quarter Adjusted EBITDA of ($0.3) million, reflecting improved operating efficiency Achieved fourth quarter gross margin of 64%, up from 48% from Q4 FY24 BioStrand segment grew over 180

    7/29/25 8:28:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ImmunoPrecise Antibodies Ltd.

    SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

    2/27/24 10:33:04 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by ImmunoPrecise Antibodies Ltd. (Amendment)

    SC 13G/A - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

    1/10/24 1:53:08 PM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ImmunoPrecise Antibodies Ltd.

    SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

    1/10/24 1:33:21 PM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPA
    Financials

    Live finance-specific insights

    View All

    ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

    ImmunoPrecise Antibodies Ltd. ("IPA", "Company", "we" or "us") (NASDAQ:IPA), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announces its financial results for the fiscal year ended April 30, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. Financial Highlights: Achieved strong revenue for Fiscal Year 2025 of $24.5 million Delivered highest-ever fourth quarter revenue of $7.0 million Reported record fourth quarter Adjusted EBITDA of ($0.3) million, reflecting improved operating efficiency Achieved fourth quarter gross margin of 64%, up from 48% from Q4 FY24 BioStrand segment grew over 180

    7/29/25 8:28:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

    The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and full fiscal year end 2025, on Tuesday, July 29, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live confere

    7/16/25 8:05:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

    Secures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU technologies to Accelerate de novo Drug Discovery. Unlocking Margin Expansion Through Scalable AI IPA Strengthens Board & Management Team Kamil Isaev, Joseph Scheffler, and Dr. Li Hui join IPA, enhancing leadership in AI, finance, and client relations. IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the third quarter ("Q3") of its 2025 fiscal year ("FY25"), which ended January 31, 2025. "As we continue to revolutionize the AI-enabled drug disc

    3/28/25 8:01:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IPA
    Leadership Updates

    Live Leadership Updates

    View All

    AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

    Arlington Capital Partners ("Arlington"), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced that its portfolio company AVS Bio, a leading global provider of critical inputs and services for the bioprocessing and biologics industries, acquired ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe" or the "Company"). IPA Europe is a carve-out of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), a biotherapeutics company leveraging proprietary technologies, including its LENSai™ platform, to accelerate the discovery of next-generation biologics. The acquisition expands AVS Bio's European footprint and adds advanced capabilities in antibody

    8/6/25 8:00:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

    ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced the appointment of Jeff Fried to its Advisory Board. A recognized leader in healthcare data infrastructure and AI innovation, Jeff Fried brings more than 25 years of experience designing and delivering high-performance data for complex life sciences and clinical environments. He currently serves as Director of Platform Strategy and Innovations for InterSystems, where he helps shape high-performance data solutions for some of the world's most demanding healthcare and life sciences environments. He has serve

    7/21/25 8:28:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

    ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately. Mr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer at Rallybio, a clinical-stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded

    7/7/25 9:00:00 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care